Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Universität Ulm · Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
795
total citations
- FWCI
- 76.27
- Percentile
- 100%
- References
- 30
Citations per year
Authors
23- SSStephan StilgenbauerCorresponding
Universität Ulm
- BEBarbara Eichhorst
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne
- JSJohannes Schetelig
TU Dresden
- SCSteven Coutré
Stanford Medicine, Stanford University
- JFJohn F. Seymour
University of Melbourne, Peter MacCallum Cancer Centre
Topics & keywords
Topics
Keywords
- Venetoclax
- Medicine
- Chronic lymphocytic leukemia
- Internal medicine
- Discontinuation
- Refractory (planetary science)
- IGHV@
- Dosing
No related works found for this paper.